Pharmaceutical Business review

Theratechnologies unveils new GRF peptide

The GRF peptide is said to have the similar potency and efficacy as that of tesamorelin and is shorter than it.

Tesamorelin is an analogue of the human growth-hormone releasing which reduces excess abdominal fat in HIV-infected patients with lipodystrophy

Theratechnologies vice-resident research Krishna Peri said the discovery of GRF peptides with improved pharmaceutical properties and similar potency and efficacy to tesamorelin gives way to alternative routes of drug delivery.